Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
Representing an investment of more than 50 million euros, this new unit dedicated to the bioproduction of pharmaceutical-grade hyaluronic acid represents a pivotal stage in the development of HTL and the largest investment ever made in the world for a biopolymer production unit.
It will enable HTL to become the largest producer of pharmaceutical-grade hyaluronic acid in the world and accelerate its international development.
Read more below.
HTL Biotechnology made a strong impact this year at IMCAS with a reinforced presence and exciting interactions with our customers and partners.
We’re happy to share that HTL Biotechnology got the new certification ISO 13485.
We’re excited to announce the publication of our first CSR Report!